A 47–year-old woman with endstage renal disease and dialysis-induced encephalopathy was being treated with carbamazepine for myoclonus. Her carbamazepine serum concentration appeared to be therapeutic at 5.1 μg/ml. She experienced a seizure while on hemodialysis/hemoperfusion that was possibly related to the removal of carbamazepine during dialysis. The elimination of carbamazepine on a dialysis day was compared with elimination on a nondialysis day. The half-life and apparent clearance were the same for each day, indicating that hemodialysis/hemoperfusion had little effect on the overall removal of carbamazepine from the body. The possible reasons for this lack of effect are discussed.
Get full access to this article
View all access options for this article.
References
1.
AkrillPRalstonAJDayJP. Role of desferoxamine in the treatment of dialysis encephalopathy. Kidney Int1986; 29 (suppl 18): S104–7.
2.
MackichanJJ. Simultaneous liquid chromatographic analysis for carbamazepine and carbamazepine 10, 11–epoxide in plasma and saliva by use of double internal standard. J Chromatogr1980; 180: 373–83.
3.
MackichanJJ. Carbamazepine. In: TaylorWJCavinessMH Diers, eds. A textbook for the clinical application of therapeutic drug monitoring. Irving, TX: Abbott Laboratories, 1986: 211–24.
4.
Carbamazepine. In: TDx system assays manual. North Chicago, IL: Abbott Laboratories, Diagnostics Division, 1987: 17.11–17.22.
5.
LesliePJHeyworthRPrescottLF. Cardiac complications of carbamazepine intoxication: treatment by hemoperfusion. Br Med J1983; 286: 1018.
6.
ChanKAguannoJJJansenRDietzlerDN. Charcoal hemoperfusion for treatment of carbamazepine poisoning. Clin Chem1981; 27: 1300–2.
7.
GaryNEByraWMEisingerRP. Carbamazepine poisoning: treatment by hemoperfusion. Nephron1981; 27: 202–3.
8.
LeeCSMarburyTCBruniJ. Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis. Clin Toxicol1980; 17: 429–38.
9.
PondSRosenbergJBenowitzNLTakkiS. Pharmacokinetics of haemoperfusion for drug overdose. Clin Pharmacokinet1979; 4: 329–54.
10.
ZiemniakJACersosimoRJRussoJMoranDMKablitzCSchentagJJ. Rebound following hemodialysis of cimetidine and its metabolites. Am J Kidney Dis1984; 3: 430–5.
11.
LeeCSMarburyTC. Drug therapy in patients undergoing hemodialysis: clinical pharmacokinetic considerations. Clin Pharmacokinet1984; 9: 42–66.
12.
RadomskiLParkGDGoldbergMJSpectorRJohnsonGFQueeCK. Model for theophylline overdose treatment with oral activated charcoal. Clin Pharmacol Ther1984; 35: 402–8.
13.
BertilssonLHojerBTybringGOsterlohJRaneA. Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther1980; 27: 83–8.
14.
EichelbaumMTorbjornTTybringGBertilssonL. Carbamazepine metabolism in man: induction and pharmacogenetic aspects. Clin Pharmacokinet1985; 10: 80–90.
